The anticipated size of the Steroid-Free Nasal Sprays Market in 2022 was USD 8,141.9 million and is estimated to be USD 8,577.5 million in 2023. Market for the global steroid-free nasal sprays market is important with the rise in demand increased number of regulatory approvals have been observed in the steroid-free nasal sprays market which is propelling the launch of innovative products. Manufacturers in the market are mainly focusing on getting regulatory approvals to improve sales in the market. Future Market Insights has mentioned in its reports that the steroid-free nasal sprays market will expand at a CAGR of 6.4% between 2023 and 2033, totaling around USD 15,908.1 million by 2033.
The global steroid-free nasal sprays market was valued at USD 7.7 billion in 2021 and is expected to reach USD 14.9 Billion by 2032, with sales growing at a 6.3% CAGR over the assessment period.
Subsequent rise has been found in the prevalence of allergies and infections worldwide where among the most prevalent type of allergy is allergic rhinitis. Allergic rhinitis includes allergies and hay fever to stimulants such as plants, mold, dust, and animal dander. The prevalence of allergic rhinitis will spur the demand for steroid-free nasal sprays in the global market.
| Attributes | Details |
|---|---|
| Projected Forecast Value (2022) | USD 8,141.9 million |
| Projected Forecast Value (2023) | USD 8,577.5 million |
| Projected Forecast Value (2033) | USD 15,908.1 million |
| Growth rate | 6.4% CAGR |
| Forecast period | 2023 to 2033 |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Global steroid-free nasal sprays market grew at a CAGR of 4.4% between 2017 and 2022. Growth forecasts remain optimistic, with the market predicted to exhibit a CAGR of 6.4% between 2023 and 2033.
Nasal routes of delivery have been in practice for decades and are widely renowned routes for topical treatment of local diseases in the nasal cavity such as allergic and non-allergic rhinitis and nasal congestion.
Advantages of nasal, mucosal, and sublingual spray delivery are well known and offer non-invasiveness (compared to injections) and easy accessibility for administration. In addition to this, greater mucosal surface area, use of a relatively large, highly vascularized, high systemic bioavailability for some drugs, avoidance of hepatic first-pass metabolism, and the potential for rapid onset of drug action can be achieved.
Easy application without the necessity of trained personnel is improving patient compliance as compared parenteral route.
Key players in the steroid-free nasal sprays market are actively focused on research and development to launch nasal sprays that can also be used as vaccines. Intranasal vaccination also provides a promising non-invasive and gentle alternative.
For instance, in March 2021, the University of Oxford began with the phase-1 clinical trial of a nasal spray formulation of its AstraZeneca-partnered COVID-19 vaccine.
Considering this, FMI expects the global steroid-free nasal sprays market to grow at a CAGR of 6.3% through 2032.
Growth and Innovation in the Pharmaceutical Industry
Growth and innovations in the pharmaceutical industry help in the manufacturing of steroid nasal-free spray products that owes to a colossal pool of health-conscious consumers creating a nasal spray market opportunity for the market. Growth of the steroid nasal-free spray market size is anticipated to be driven by the high potentiality in untapped, emerging markets, because of the presence of improved healthcare infrastructure, with the rise in unmet healthcare needs and a rise in the prevalence of chronic respiratory disease. Healthcare industry in emerging economies is considered to be developing at a compelling rate, which owes to a rise in demand for enhanced healthcare services, significant investments by the government to improve healthcare infrastructural, and the development of the medical tourism industry in emerging countries.
Principal Consultant
Availability of Preservative-free Formulations or Dry Powders Offering Opportunities to its Consumers
Recent developments are addressing the medical needs for depression, the CNS comprises various areas, some of which are with high unmet medical needs which includes schizophrenia, Alzheimer’s disease, Parkinson’s disease, insomnia, ADH, bipolar, and anxiety disorders, where non-invasive nasal delivery could prove to be beneficial.
Nasal sprays that contain preservative-free formulations or dry powders offer opportunities to avoid the use of preservatives and their potential complications. Typical preservatives such as benzalkonium chloride, parabens, and ethylene diamine tetra-acetic acid (EDTA) have been reported to cause damage to the nasal mucosa when used in chronic therapies and have side effects such as hindrance of the ciliary clearing functions within the nasal cavity.
Higher preference for preservative-free formulations to avoid these side effects which will create opportunities for the steroid-free nasal sprays market.
Prolonged Usage of the Nasal Spray Effect the Receptors on the Blood Vessels in the Nose
Nasal sprays provide a very safe and effective treatment for allergic rhinitis when taken for a short length of time as it is only recommended for a maximum of three days in a row.
Prolonged usage of the nasal spray may cause the receptors on the blood vessels in the nose to be downregulated which means when the number of receptors decreases, a rebound response of nasal inflammation, known as rhinitis medicamentosa, may develop when the user quits taking the drug. Long-term usage of certain sprays might harm tissue, resulting in infection and pain.
Patients who use a nasal spray regularly develop the habit of overusing the drug which causes different complications, and it is a setback for the growth of the steroid-free nasal spray market.
Several products have been recalled from the steroid-free nasal spray market due to the side effect observed, thus, these factors are expected to limit sales in the market over the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Consumers are Preferring Steroid-free Nasal Sprays for Allergies
North America holds a major portion of the market share at 35.4% whereas the United States holds a dominant part with a market share of 32.8%
United States accounted for 92% of the North American steroid-free nasal sprays market in 2021 and is expected to continue its dominance over the forecast period. Key players in the USA are focusing to bring differentiated products to address unmet needs regarding allergic rhinitis.
Expansion for Therapeutic Applications for Steroid-free Nasal Sprays
Europe is said to hold a market share of 29.4% whereas Germany holds a market share of 7.1% and the United Kingdom is said to grow in the market at a CAGR of 6.0%
Provision of intranasal administration in various useful options for the local and systemic delivery of diversified therapeutic agents for the treatment of allergies, respiratory diseases, etc.
Rising Preference for Steroid-free Allergy Nasal Sprays in Japan Will Fuel Growth
Japan is an emerging market for steroid-free nasal sprays and accounted for a market share of 5.3% in the East Asia steroid-free nasal sprays market, owing to the increasing prevalence of allergic rhinitis in the country.
According to the Japanese Society of Allergology, the prevalence of perennial allergic rhinitis is common among young people and there is a significant rise in the cases of allergic rhinitis.
Players in the country are promoting their products through online channels. For instance, in January 2021, Avantor, Inc, launched its Japanese e-commerce website, jp.vwr.com to better serve customers locally with access to the company's broad portfolio of products and services, and related information.
Expansion in the Pharmaceutical Sector in India Will Boost Sales of Steroid-free Nasal Sprays
India accounted for more than 45% of the South Asia market growing at a CAGR of 7.2%. Manufacturers in India are launching generic versions that are less expensive to improve sales. increase the reach of the products to their customers.
Rise in Allergic-Rhinitis acts as a Serious Health Problem
Steroid-free nasal spray market in China is said to grow at a CAGR of 7.0%
Allergic rhinitis (AR) acts a serious problem for public health and medical concern because it acts as a risk factor that causes several disorders and diseases, mainly in children thus, rising, and significantly impacting the Chinese population.
Demand for Nasal Antihistamine Sprays Will Gain Momentum
Sales of nasal antihistamine sprays will increase at a market share of 34.60% over the assessment period, as these sprays are the most widely used due to their clinical benefits and the least side effects.
Nasal antihistamine sprays are used to treat seasonal allergies, allowing a person to apply the medicine directly to the nose and help in treating the allergy symptoms at the source and may cause fewer side effects than pills.
Individuals are Preferring Aqueous Steroid-free Nasal Sprays for Allergies
Aqueous by-formulation segment dominated the steroid-free nasal sprays market with a 55.05% value share as they account for the highest market share because it provides rapid drug absorption into the mucous membrane as highly adopted by individuals as they are easier to use and widely available.
Sales of Steroid-free Nasal Sprays Through Institutional Channels Remain High
Sales in the institutional segment are expected to increase at a 6% CAGR over the assessment period where the segment is accounted for 57.7% of the total market share. Increasing need for steroid-free nasal sprays for respiratory allergies, and frequent prescriptions by doctors are propelling sales in hospitals and specialty clinic settings.
Some of the prominent players in the global market are-
Some of the important developments of the key players in the market are:
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 6.4% from 2023 to 2033 |
| Market value in 2023 | USD 8,577.5 million |
| Market value in 2033 | USD 15,908.1 million |
| Base Year for Estimation | 2022 |
| Historical Data | 2017 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | USD million for Value and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | By Country, By Product Type, By Formulation, By Distribution Channel |
| Regions Covered | North America; Latin America; Western Europe; Eastern Europe; South Asia and Pacific; East Asia; Middle East & Africa |
| Key Countries Profiled | United States, Canada, Brazil, Mexico, Rest of Latin America, Germany, United Kingdom, France, Spain, Italy, Rest of Europe, China, Japan, South Korea, Singapore, Thailand, Indonesia, Australia, New Zealand, Rest of Asia Pacific, GCC countries, South Africa, Israel, Rest of MEA |
| Key Companies Profiled | Janssen Pharmaceutical, Inc.; Astra Zeneca Plc.; Cipla Ltd.; Glenmark Pharmaceuticals; Glaxosmithkline Plc.; Novartis International AG; Procter & Gamble; Sanofi S.A. (Sanofi-aventis LLC.); Boehringer Ingelheim GmbH; AdvaCare Pharma; Bayer AG (Bayer Consumer Health; Covis Pharma S.a.r.l.; Nipro Corporation (NIPRO JMI Pharma ;Ltd.); Viatris Inc. (Meda Pharmaceuticals Inc.); Perrigo Company plc; AptarGroup, Inc.; Berry Global, Inc.; URSATEC GmbH; Gerresheimer AG; Avantor, VWR International, LLC |
| Customisation Scope | Available on Request |
From 2018 to 2022, sales increased at a CAGR of 4.4%.
The market is expected to continue to evolve at a 6.4% CAGR through 2033.
The market is expected to climb to USD 15,908.1 million by 2033.
The market is expected to be valued at USD 8,577.5 million in 2023.
North America accounts for a significant part of the market, encompassing 35.4%.
With a market share of 32.8%, the United States dominates.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product 5.1. Antihistamine 5.2. Decongestant 5.3. Anticholinergic 5.4. Cromolyn Sodium 5.5. Others 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Formulation 6.1. Aqueous 6.2. Suspension 6.3. Nonaqueous-Based Solution 6.4. Hydroalcoholic 6.5. Emulsions 6.6. Dry Powder/Micro Particles 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 7.1. Institutional Sales 7.1.1. Hospitals 7.1.2. Specialty Clinics 7.1.3. Community Clinics 7.1.4. Public Health Agencies 7.1.5. Others 7.2. Retail Sales 7.2.1. Retail Pharmacy 7.2.2. Drug Stores 7.2.3. Mail Order Pharmacy 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Western Europe 8.4. Eastern Europe 8.5. South Asia and Pacific 8.6. East Asia 8.7. Middle East and Africa 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16. Key Countries Market Analysis 17. Market Structure Analysis 18. Competition Analysis 18.1. Janssen Pharmaceutical, Inc. 18.2. Astra Zeneca Plc. 18.3. Cipla Ltd. 18.4. Glenmark Pharmaceuticals 18.5. Glaxosmithkline Plc. 18.6. Novartis International AG 18.7. Procter & Gamble 18.8. Sanofi S.A. (Sanofi-aventis LLC.) 18.9. Boehringer Ingelheim GmbH 18.10. AdvaCare Pharma 18.11. Bayer AG (Bayer Consumer Health) 18.12. Covis Pharma S.a.r.l. 18.13. Nipro Corporation (NIPRO JMI Pharma Ltd.) 18.14. Viatris Inc. (Meda Pharmaceuticals Inc.) 18.15. Perrigo Company plc 18.16. AptarGroup, Inc. 18.17. Berry Global, Inc. 18.18. URSATEC GmbH 18.19. Gerresheimer AG 18.20. Avantor, VWR International, LLC 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Steroid-Free Nasal Sprays Market
